C.12 modified erythromycin a derivatives

Details C.12 modified erythromycin a derivatives C.12 modified erythromycin a derivatives

C - Chemistry, Metallurgy

07

H

167/185, 260/230

C07H 17/08 (2006.01) A61K 31/71 (1990.01)

Patent

CA 1296718

72222-87 ABSTACT OF THE DISCLOSURE Erythromycin A derivatives of the formula: (3) Image (wherein: R is hydroyen or (C2-C4)alkanoyl; R1 and R2 are taken separately, R1 is hydxoxymethyl and R2 is hydroxy; or R1 and R2 are taken together and are methylene; and R3 and R4 are taken separately and are each hydro- gen; or R3 and R4 are taken together and are thiocarbonyl; with the proviso that when R3 and R4 are so taken, R is other than hydrogen); and their pharmaceutical acceptable acid addition salts are anti- bacterial and useful as active ingredients of pharmaceuticals. These derivatives can be produced by selective formation of the exocylic double bond at the C-12 position (i.e., when R1 and R2 are methylene) from corresponding 12-beta-hydroxy-12-alpha-methyl compounds while the 9 and 11-hydroxyl groups are thiocarbonate, followed by diol formation and/or deacylation as required.

574578

Affiliated with

Also associated with

Rating

C.12 modified erythromycin a derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with C.12 modified erythromycin a derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C.12 modified erythromycin a derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1317817